focus -WSS

focus

author：explore 2025-09-28 00:48:02 - browse：7353

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： HHS names first

WSS

CDC recommends RSV monoclonal antibody for infants

The a glaring gap in research on serious mental illness and primary care

How to ethically and practically extend health care to all

GSK to buy asthma

How I ended up pumping milk in a bathroom stall at JPM 2024

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The cancer stories no one wants to hear

Virginia high school admissions case could be legal follow

HHS names first

Hollywood unions extend contract negotiations for actors

Caregivers of transplant patients call for more support, training

Sports medicine is finally prioritizing gender equality

Risky weight loss products often used by teens globally, per study

Cancer drug shortages should be causing more outrage

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

knowledge

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Fauci’s Covid grilling leads GOP to weigh foreign research rules

How to ethically and practically extend health care to all

As JPM 2024 winds down, some health tech firms project optimism

It costs an awful lot of money to give away a kidney

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Wikipedia

leisure time

hotspot

leisure time